ECP
MACK

Empyrean Capital Partners’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Empyrean Capital Partners’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-5,084
Closed -$152K – 73
2013
Q3 		$152K Buy
+5,084
New +$178K ﹤0.01% 59

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Empyrean Capital Partners's MACK Position: Q4 2013 in Review

Empyrean Capital Partners sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2013, closing a stake of 5,084 shares — an estimated $152K sold.

Empyrean Capital Partners first reported a position in MACK in Q3 2013 and held it in 1 quarter. The position peaked at $152K in Q3 2013. 93 funds tracked by Wall St. Rank hold MACK as of Q4 2013.

  • Empyrean Capital Partners reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2013 after selling out during the quarter.
  • Empyrean Capital Partners sold 5,084 Merrimack Pharmaceuticals, Inc. shares in Q4 2013, an estimated $152K.
  • Empyrean Capital Partners first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 1 quarter.
  • Empyrean Capital Partners's Merrimack Pharmaceuticals, Inc. position peaked at $152K in Q3 2013.
  • 93 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2013.

Based on Empyrean Capital Partners's 13F filing for Q4 2013, filed 13 Feb 2014.